Microbiome Therapeutics Market by Product Type (Probiotics, Prebiotics, Synbiotics (Combination of Prebiotics and Probiotics)), By Disease Indication (Digestive-related disorders (Crohn’s disease, Inflammatory Bowel Disease (IBD), Irritable Bowel Syndrome (IBS), Others)), Metabolic Disorders (Obesity, Diabetes, Others), Respiratory Infections, Cancer, Immune System, Oral Diseases, Skin Infections, and Others) and Geography


Purchase Option

$ 3000
$ 4400
$ 6600
$ 8900

Microbiome Therapeutics Market Size was valued at USD 321.58 million in 2021 and is estimated to reach 1338.82 million by 2028, at a CAGR of 22.6% during the forecast period 2022 to 2028. A microbiome is the genetic material of all microbes such as bacteria, viruses, fungi, and protozoa that live on and inside the human body. Every part of the body has different types of microbes. For instance, about a third of bacteria in the gut are Bacteroides species, whereas Streptococcus species are dominant in oral health. The market plays a significant role in human health and disease conditions. The global microbiome therapeutics market is still nascent stage, very few products in the market are currently approved to treat various therapeutic conditions. Start-ups are very active in terms of microbiome therapeutics market growth, product launches, research, and development activities. However, bigger players in the microbiome therapeutics market are focused to provide funding, collaborating, and acquiring smaller players to promote the research activities. Furthermore, Venture Capitalists and Government Organisations are actively involved in funding and encouraging research activities. The launch of microbiome therapeutics products in the market is expected to fuel the demand of the market over the forecast.  For instance, in May 2014, Pfizer entered an agreement with Second Genome to conduct research on obesity and metabolic disorders. In April 2016, the company also raised US$ 42.6 Mn in Series B funding led by Pfizer Venture Investments and Roche Venture Fund. The funding amount will be used to conduct the clinical investigation on SGM-109, a small molecule inhibitor of a microbiome-mediated target to address inflammation and pain conditions in ulcerative colitis. In February 2016, Synlogic raised US$ 40 Mn in Series B from OrbisMed Healthcare Fund Management to expand its research programs on inflammatory bowel disease conditions and to develop therapeutics for inborn errors of metabolism of Urea Cycle Disorder and Phenylketonuria conditions. Key Developments: In July 2016, Series Therapeutics started a clinical trial on its synthetically designed microbiome drug SER-262, to treat Clostridium difficile infection conditions. The study is currently enrolling patients from 22 locations in the U.S. In February 2015, 4D Pharma plc, U.K. based company, acquired Tucana involved in the development of microbiome therapeutics products to treat Irritable Bowel Syndrome (IBS) conditions In January 2016, Takeda Pharmaceuticals Ltd and Enterome entered a strategic drug discovery collaboration to conduct research and development on novel therapeutics that target the microbiome that plays crucial roles in multiple gastrointestinal disease conditions

Global Mircobiome Therapeutics Market Summary

Study Period


Base Year




Largest Market


Fastest Growing Market

North America
Mircobiome Therapeutics Market Dynamics

Increase in evidence about the direct relationship of the microbiome in treating lifestyle diseases, autoimmune diseases such as Crohn’s, inflammatory bowel disease (IBS) conditions are fuelling the growth of the market. Currently, very few drugs are available in the market to treat these disease conditions. Furthermore, microbiome therapeutics are safer than conventional treatments as they are already present in the human body. Microbiome therapeutics didn’t possess any side-effects, unlike conventional drugs these factors will have a positive impact on the growth of the market. However, the lack of substantial clinical evidence about the microbiome benefits on human health and regulatory barriers might hamper the growth of the market over the forecast period.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

Global Mircobiome Therapeutics Market Segmentation

By Product Type
  • Probiotics
  • Prebiotics
  • Synbiotics (Combination of Prebiotics and Probiotics)
Disease Indication
  • Digestive related disorders
    • Crohn’s disease
    • Inflammatory Bowel Disease (IBD)
    • Irritable Bowel Syndrome (IBS)
    • Others
  • Metabolic Disorders
    • Obesity
    • Diabetes
    • Others
  • Respiratory Infections
  • Cancer
  • Immune System
  • Oral Diseases
  • Skin Infections
  • Others
By Geography
  • North America,
  • Europe,
  • Asia Pacific,
  • Latin America and
  • Middle East and Africa.

Frequently Asked Questions

The microbiome therapeutics market is projected to expand at a CAGR of 22.6% during the forecast period

AB biotics, Enterome, Seres Therapeutics, Vedanta Biosciences, Eligo Bioscience, 4D Pharma plc, Synlogic, TargEDys

North America is the fastest-growing region for microbiome therapeutics market

[urltag url='request-table-of-content']

  • Johnson & Johnson
  • Pfizer Inc.
  • AB biotics
  • Enterome
  • Seres Therapeutics
  • Vedanta Biosciences
  • Eligo Bioscience
  • 4D Pharma plc
  • Synlogic
  • TargEDys
  • Second Genome
  • LNC research & development
  • Takeda Pharmaceutical Company Ltd
  • Ritter Pharmaceuticals.